This study investigates treatment options for patients with pancreatic cancer.
The study evaluates the safety, tolerability, and effectiveness of CAR-NK cells in patients with pancreatic cancer.
- Who can participate: Adults aged 18 to 70 with locally advanced, metastatic, or recurrent pancreatic cancer who meet specific health criteria and have not received recent anti-tumor treatment may be eligible.
- Study details: Participants will receive an investigational treatment involving CAR-NK cells.